ECSP12011701A - Anticuerpos anti-cdcp1 humanizados - Google Patents

Anticuerpos anti-cdcp1 humanizados

Info

Publication number
ECSP12011701A
ECSP12011701A ECSP12011701A ECSP12011701A EC SP12011701 A ECSP12011701 A EC SP12011701A EC SP12011701 A ECSP12011701 A EC SP12011701A EC SP12011701 A ECSP12011701 A EC SP12011701A
Authority
EC
Ecuador
Prior art keywords
humanized anti
antibodies
cdcp1
cdcp1 antibodies
humanized
Prior art date
Application number
Other languages
English (en)
Inventor
Guy Georges
Johannes Auer
Birgit Bossenmaier
Gerhard Niederfellner
Alexander Lifke
Ekkehard Moesnner
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of ECSP12011701A publication Critical patent/ECSP12011701A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a anticuerpos humanizados contra la CDCP1 humana (anticuerpos anti-CDCP1), a métodos para su producción, a composiciones farmacéuticas que contienen dichos anticuerpos y a los usos de los mismos.
ECSP12011701 2009-08-28 2012-02-28 Anticuerpos anti-cdcp1 humanizados ECSP12011701A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09011046 2009-08-28
EP10000972 2010-02-01

Publications (1)

Publication Number Publication Date
ECSP12011701A true ECSP12011701A (es) 2012-03-30

Family

ID=43086176

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011701 ECSP12011701A (es) 2009-08-28 2012-02-28 Anticuerpos anti-cdcp1 humanizados

Country Status (23)

Country Link
US (2) US8394928B2 (es)
EP (1) EP2470567A1 (es)
JP (1) JP5647687B2 (es)
KR (1) KR101495407B1 (es)
CN (1) CN102482357B (es)
AR (1) AR077973A1 (es)
AU (1) AU2010288879A1 (es)
BR (1) BR112012004221A2 (es)
CA (1) CA2770161A1 (es)
CL (1) CL2012000524A1 (es)
CO (1) CO6511201A2 (es)
CR (1) CR20120038A (es)
EC (1) ECSP12011701A (es)
IL (1) IL217919A0 (es)
MA (1) MA33537B1 (es)
MX (1) MX2012002458A (es)
NZ (1) NZ597664A (es)
PE (1) PE20121063A1 (es)
RU (1) RU2571207C2 (es)
SG (1) SG178886A1 (es)
TW (1) TWI412375B (es)
UA (1) UA106890C2 (es)
WO (1) WO2011023389A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201113037A (en) * 2009-08-28 2011-04-16 Hoffmann La Roche Antibodies against CDCP1 for the treatment of cancer
TWI412375B (zh) * 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體
KR20130118941A (ko) 2011-02-10 2013-10-30 로슈 글리카트 아게 면역치료법
MY175687A (en) 2012-08-07 2020-07-06 Roche Glycart Ag Composition comprising two antibodies engineered to have reduced and increased effector function
AU2013359419B2 (en) 2012-12-10 2018-03-15 Biogen Ma Inc. Anti-blood dendritic cell antigen 2 antibodies and uses thereof
WO2014172448A2 (en) * 2013-04-17 2014-10-23 Anaptysbio, Inc. Antibodies directed against activin receptor type ii (actrii)
WO2015082446A1 (en) 2013-12-02 2015-06-11 F. Hoffmann-La Roche Ag Treatment of cancer using an anti-cdcp1 antibody and a taxane
MX2016009653A (es) 2014-01-24 2017-03-27 Henry M Jackson Found Advancement Military Medicine Inc Anticuerpos contra glicoproteina f de virus hendra y nipah.
US20170158753A1 (en) * 2014-06-25 2017-06-08 Integrated Biotherapeutics, Inc. Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species
EP3554544A4 (en) 2016-12-16 2020-07-29 Bluefin Biomedicine, Inc. ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE
US10928391B2 (en) * 2017-06-06 2021-02-23 The Cleveland Clinic Foundation CD318 as a marker for, and CD318 inhibition as a treatment for, autoimmune disease
EP3700930A1 (en) 2017-10-25 2020-09-02 The Regents of the University of California Antibodies against cdcp1 for the treatment and detection of cancer
US12371507B2 (en) 2018-11-09 2025-07-29 Beth Israel Deaconess Medical Center CDCP1 antibodies and antibody drug conjugates
JP2022523746A (ja) * 2019-02-01 2022-04-26 フォンダツィオーネ・ペア・リスチチュート・オンコロジコ・ディ・リチェルカ・（イオエッレ） 去勢抵抗性前立腺がんを処置する方法
JP7623705B2 (ja) * 2019-12-27 2025-01-29 株式会社カイオム・バイオサイエンス 抗ｃｄｃｐ１抗体
KR102911451B1 (ko) * 2022-05-24 2026-01-09 건국대학교 글로컬산학협력단 Rps3 결합 단클론 항체 및 이의 용도
CN117264055A (zh) * 2022-06-14 2023-12-22 上海恒润达生生物科技股份有限公司 一种特异性结合人cd318的vhh抗体或其抗原结合片段及其制备方法和应用
CA3259098A1 (en) * 2022-06-20 2025-04-18 Sichuan Huiyu Seacross Pharmaceutical Technology Co., Ltd. ANTIBODIES AND THEIR USES
CA3261603A1 (en) 2022-07-15 2024-01-18 Pheon Therapeutics Ltd ANTIBODY-DRUG CONJUGATES
KR20240057529A (ko) * 2022-10-24 2024-05-03 주식회사 노벨티노빌리티 신규 항-cdcp1 항체 및 이의 용도
WO2025199124A1 (en) * 2024-03-19 2025-09-25 Tavotek Lab Inc Antibodies targeting cd318 (cdcp1) and uses thereof
WO2025207944A1 (en) * 2024-03-29 2025-10-02 Sidewinder Therapeutics, Inc. Fgfr3-iiib-binding antibodies
WO2025262641A1 (en) 2024-06-19 2025-12-26 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof
WO2026078443A1 (en) 2024-10-11 2026-04-16 Pheon Therapeutics Ltd. Antibody drug conjugates that bind cdcp1 and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
WO1998002462A1 (en) * 1996-07-16 1998-01-22 Morphosys Gesellschaft Für Proteinoptimierung Mbh Immunoglobulin superfamily domains and fragments with increased solubility
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
CN1329061A (zh) 2000-06-19 2002-01-02 上海博德基因开发有限公司 一种新的多肽——人g蛋白亚基9.46和编码这种多肽的多核苷酸
EP1301533A1 (de) 2000-07-07 2003-04-16 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Tumorassoziiertes antigen (b345), gekennzeichnet durch eine aminosäuresequenz wie in seq. id. no. 4
NZ571596A (en) * 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
DE10242146A1 (de) 2002-09-04 2004-03-18 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper zur Identifizierung und/oder Isolierung von hämatopoetischen Stammzellen
EP2248892B1 (en) 2003-01-22 2015-04-22 Roche Glycart AG Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function
CN100422328C (zh) 2003-02-19 2008-10-01 诺瓦提斯公司 在人转移性肿瘤细胞中表达的糖蛋白抗原sima135
EP1648511A1 (en) 2003-07-29 2006-04-26 Morphotek, Inc. Antibodies and methods for generating genetically altered antibodies with enhanced effector function
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
AU2004273791A1 (en) 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
GB0324656D0 (en) 2003-10-22 2003-11-26 Celltech R&D Ltd A protein involved in ovarian cancer
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
US20080008719A1 (en) 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
WO2006114700A2 (en) 2005-04-26 2006-11-02 Bioren, Inc. Method of producing human igg antibodies with enhanced effector functions
WO2007005502A2 (en) * 2005-06-30 2007-01-11 Applera Corporation Methods and compositions for treating diseases targeting cdcp1
AU2006290433B2 (en) 2005-08-26 2012-06-07 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
JP2007112734A (ja) * 2005-10-19 2007-05-10 Chugai Pharmaceut Co Ltd 抗ｃｄｃｐ１抗体を含有する癌細胞増殖抑制剤
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
TWI412375B (zh) * 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體

Also Published As

Publication number Publication date
MX2012002458A (es) 2012-03-14
TWI412375B (zh) 2013-10-21
UA106890C2 (uk) 2014-10-27
KR20120089658A (ko) 2012-08-13
CO6511201A2 (es) 2012-08-31
JP5647687B2 (ja) 2015-01-07
SG178886A1 (en) 2012-04-27
NZ597664A (en) 2013-03-28
RU2571207C2 (ru) 2015-12-20
RU2012111708A (ru) 2013-10-10
AU2010288879A1 (en) 2012-02-02
WO2011023389A1 (en) 2011-03-03
BR112012004221A2 (pt) 2016-11-29
KR101495407B1 (ko) 2015-02-24
US20130209455A1 (en) 2013-08-15
HK1167412A1 (en) 2012-11-30
IL217919A0 (en) 2012-03-29
CN102482357A (zh) 2012-05-30
AR077973A1 (es) 2011-10-05
US8394928B2 (en) 2013-03-12
US20110052582A1 (en) 2011-03-03
CL2012000524A1 (es) 2012-08-17
PE20121063A1 (es) 2012-08-09
EP2470567A1 (en) 2012-07-04
US9346886B2 (en) 2016-05-24
MA33537B1 (fr) 2012-08-01
TW201110983A (en) 2011-04-01
CA2770161A1 (en) 2011-03-03
JP2013502904A (ja) 2013-01-31
CN102482357B (zh) 2014-06-11
CR20120038A (es) 2012-04-18

Similar Documents

Publication Publication Date Title
ECSP12011701A (es) Anticuerpos anti-cdcp1 humanizados
CR20120215A (es) Anticuerpos contra csf-1r humano y usos de los mismos
ECSP11011387A (es) Anticuerpos biespecíficos anti-erbb-3/anti-c-met
CO7081144A2 (es) Anticuerpos biespecíficos contra tweak humana e il17 humana y usos de los mismos
CO6351794A2 (es) Anticuerpos biespecificos anti-vegf/anti-ang-2
ECSP12011995A (es) Anticuerpos anti-her3 y usos de los mismos
CR20120184A (es) Anticuerpos monoclonales frente a progastrina y su usos
ECSP13011139A (es) Anticuerpos contra la angiopoyetina 2 humana
CO6362023A2 (es) Anticuerpos biespecificos anti-egfr/ anti-igf-1r
MX338078B (es) Cristales de anticuerpos anti-esclerostina y formulaciones de los mismos.
CR20150502A (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización
ECSP10010295A (es) Formulacion de anticuerpo
GT201300306A (es) Anticuerpos anti-angptl3 y usos de los mismos
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
MX2019003738A (es) Compuestos antivirales.
CO6630087A2 (es) Anticuerpos bivalentes biespecificos anti-vegf/anti-ang-2
ECSP13012649A (es) Anticuerpos ANTI-IL-23
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
NI201400061A (es) Anticuerpos anti - phf - tau y sus usos
UY34456A (es) Anticuerpos anti-il-36r
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
HN2010001537A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
ECSP13012481A (es) Composiciones de anticuerpo anti-vegfr-3
AR089079A1 (es) Formulacion de anticuerpo anti-cd44
GT201200066A (es) Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen